In 2004, doctors told my husband Mike there was nothing more they could do—the pancreatic cancer he was diagnosed with would soon take his life.
“As Iowa goes, so goes the nation.”
Cancer clinical trials shouldn’t discriminate—but they do
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy, plus Keytruda (pembrolizumab) improved recurrence-free survival and distant metastasis-free survival as an adjuvant treatment for patients with completely resected stage 2B-4 melanoma, according to results of the phase III INTerpath-001 trial.
Rasonque (daraxonrasib) consistently provided an overall survival benefit compared with chemotherapy across all evaluated RAS genotype subgroups among patients with previously treated metastatic pancreatic adenocarcinoma, including those with no identified tumor RAS mutation, according to exploratory subgroup analyses from the phase III RASolute 302 trial.
Nivolumab plus ipilimumab, with or without stereotactic body radiotherapy, produced a 100% objective response rate among evaluable patients with advanced Merkel cell carcinoma who had not previously received immune checkpoint inhibitors, according to a long-term analysis of a randomized phase II trial.
Camupepimut (ELI-002 7P) demonstrated consistent and favorable treatment-effect trends in patients with and without detectable baseline ctDNA and in patients without prior radiation across multiple pre-specified analyses, according to the results of a randomized phase II study of patients with resected pancreatic ductal adenocarcinoma called AMPLIFY-7P.
APN401, an autologous PBMC (peripheral blood mononuclear cell) therapy, demonstrated a favorable safety profile, with no dose-limiting toxicities or grade ≥3 treatment-related adverse events, according to the results from two phase I studies evaluating APN401 in patients with advanced, treatment-refractory solid tumors.
